search
Back to results

CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Primary Purpose

Acute Myeloid Leukemia

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
CART-19
Sponsored by
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Myeloid Leukemia

Eligibility Criteria

6 Years - 65 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female patients with CD19+ relapsed/refractory acute myeloid leukemia
  • Age 6-65 years.
  • Left ventricular ejection fractions≥ 0.5 by echocardiography.
  • Creatinine < 1.6 mg/dL.
  • Aspartate aminotransferase/aspartate aminotransferase < 3x upper limit of normal.
  • Bilirubin <2.0 mg/dL.
  • Karnofsky performance status ≥ 60
  • Expected survival time ≥ 3 months (according to investigator's judgement)

Exclusion Criteria:

  • Pregnant or lactating women.
  • Uncontrolled active infection.
  • Active hepatitis B or hepatitis C infection.
  • Class III/IV cardiovascular disability according to the New York Heart Association Classification.
  • HIV infection.
  • Patients with history of seizure
  • Active central nervous system leukemia

Sites / Locations

  • The First Affiliated Hospital of Soochow UniversityRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

CD19 positive relapsed or refractory acute myeloid leukemia

Arm Description

MICM typing confirmed CD19 positive relapsed and refractory acute myeloid leukemia

Outcomes

Primary Outcome Measures

Adverse events
Adverse events are evaluated with CTCAE V4.03

Secondary Outcome Measures

Full Information

First Posted
March 25, 2019
Last Updated
May 18, 2022
Sponsor
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT03896854
Brief Title
CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Official Title
Pilot Study of the Efficacy and Safety of CD19 Targeted Chimeric Antigen Receptor Engineered T Cell in the Treatment of Relapsed or Refractory CD19 Positive Acute Myeloid Leukemia (AML)
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Recruiting
Study Start Date
October 18, 2017 (Actual)
Primary Completion Date
January 18, 2023 (Anticipated)
Study Completion Date
January 28, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This is a single center, open-label phase 1/2 study to evaluate the safety and efficacy of targeted CD19 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of CD19 positive relapsed or refractory acute myeloid leukemia.
Detailed Description
The patients will receive infusion of CART cells targeting CD19 to confirm the safety and efficacy of CD19 CART Cells in relapsed or refractory acute myeloid leukemia.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Myeloid Leukemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
CD19 positive relapsed or refractory acute myeloid leukemia
Arm Type
Experimental
Arm Description
MICM typing confirmed CD19 positive relapsed and refractory acute myeloid leukemia
Intervention Type
Biological
Intervention Name(s)
CART-19
Intervention Description
CART-19 Split intravenous infusion of CART-19 cells of (Dose escalating infusion of 1 - 20 x10^6 CART-19 cells/kg).
Primary Outcome Measure Information:
Title
Adverse events
Description
Adverse events are evaluated with CTCAE V4.03
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female patients with CD19+ relapsed/refractory acute myeloid leukemia Age 6-65 years. Left ventricular ejection fractions≥ 0.5 by echocardiography. Creatinine < 1.6 mg/dL. Aspartate aminotransferase/aspartate aminotransferase < 3x upper limit of normal. Bilirubin <2.0 mg/dL. Karnofsky performance status ≥ 60 Expected survival time ≥ 3 months (according to investigator's judgement) Exclusion Criteria: Pregnant or lactating women. Uncontrolled active infection. Active hepatitis B or hepatitis C infection. Class III/IV cardiovascular disability according to the New York Heart Association Classification. HIV infection. Patients with history of seizure Active central nervous system leukemia
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Xiaowen Tang, Ph.D.
Phone
(0086)51267781856
Email
tangxiaowen@suda.edu.cn
First Name & Middle Initial & Last Name or Official Title & Degree
Lei Yu, Ph.D.
Phone
(0086)13818629089
Email
ylyh188@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Xiaowen Tang, Ph.D.
Organizational Affiliation
The First Affiliated Hospital of Soochow University
Official's Role
Principal Investigator
Facility Information:
Facility Name
The First Affiliated Hospital of Soochow University
City
Suzhou
State/Province
Jiangsu
ZIP/Postal Code
215000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xiaowen Tang, Ph.D.

12. IPD Sharing Statement

Learn more about this trial

CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

We'll reach out to this number within 24 hrs